We are live on ! Find out more
SPHS

Sophiris Bio, Inc.
SPHS

Delisted

SPHS was delisted on the 11th of March, 2020.

18 hedge funds and large institutions have $14.3M invested in Sophiris Bio, Inc. in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

13.06% less ownership

Funds ownership: 50.9%37.84% (-13%)

25% less funds holding

Funds holding: 2418 (-6)

48% less capital invested

Capital invested by funds: $27.4M → $14.3M (-$13.1M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
18
Holders Change
-6
Holders Change %
-25%
% of All Funds
0.52%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
1
Reduced
4
Closed
7
Calls
Puts
Net Calls
Net Calls Change

SPHS Hedge Fund Activity: Q2 2014 in Review

18 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q2 2014, worth a combined $14.3M — down 48% from $27.4M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SPHS and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 1 added.

The largest buyer was Great Point Partners, adding an estimated $253K. The largest seller was Fidelity Investments, exiting entirely with an estimated $4.77M sold.

  • 18 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q2 2014, down from 24 in Q1 2014.
  • Funds reported $14.3M of Sophiris Bio, Inc. stock for Q2 2014, down 48% quarter-over-quarter.
  • 1 fund opened new Sophiris Bio, Inc. positions in Q2 2014 and 7 closed out, a net change of -6 holders.
  • The largest Sophiris Bio, Inc. buyer in Q2 2014 was Great Point Partners, an estimated $253K added.
  • The largest Sophiris Bio, Inc. seller in Q2 2014 was Fidelity Investments, an estimated $4.77M sold.

Based on aggregated 13F filings for Q2 2014.